Advances in the design and delivery of RNA vaccines for infectious diseases
(2024) In Advanced Drug Delivery Reviews 213.- Abstract
RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of global significance, e.g., infectious diseases. The highly successful messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed at record speed during the coronavirus disease 2019 pandemic. A consequence of this is exceptionally shortened vaccine development times, which in combination with adaptability makes the RNA vaccine technology highly attractive against infectious diseases and for pandemic preparedness. Here, we review state of the art in the design and delivery of RNA vaccines for infectious diseases based on different RNA modalities, including linear mRNA, self-amplifying RNA,... (More)
RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of global significance, e.g., infectious diseases. The highly successful messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed at record speed during the coronavirus disease 2019 pandemic. A consequence of this is exceptionally shortened vaccine development times, which in combination with adaptability makes the RNA vaccine technology highly attractive against infectious diseases and for pandemic preparedness. Here, we review state of the art in the design and delivery of RNA vaccines for infectious diseases based on different RNA modalities, including linear mRNA, self-amplifying RNA, trans-amplifying RNA, and circular RNA. We provide an overview of the clinical pipeline of RNA vaccines for infectious diseases, and present analytical procedures, which are paramount for characterizing quality attributes and guaranteeing their quality, and we discuss future perspectives for using RNA vaccines to combat pathogens beyond SARS-CoV-2.
(Less)
- author
- Lokras, Abhijeet Girish ; Bobak, Thomas Rønnemoes ; Baghel, Saahil Sandeep ; Sebastiani, Federica LU and Foged, Camilla
- organization
- publishing date
- 2024-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Delivery systems, Infectious diseases, Lipid nanoparticles, Nanomedicine, RNA, Vaccines, Vaccinology
- in
- Advanced Drug Delivery Reviews
- volume
- 213
- article number
- 115419
- publisher
- Elsevier
- external identifiers
-
- pmid:39111358
- scopus:85201788337
- ISSN
- 0169-409X
- DOI
- 10.1016/j.addr.2024.115419
- language
- English
- LU publication?
- yes
- id
- eccac970-5470-47e9-af93-22a089e043d6
- date added to LUP
- 2024-10-30 13:26:26
- date last changed
- 2025-07-10 11:59:10
@article{eccac970-5470-47e9-af93-22a089e043d6, abstract = {{<p>RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of global significance, e.g., infectious diseases. The highly successful messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed at record speed during the coronavirus disease 2019 pandemic. A consequence of this is exceptionally shortened vaccine development times, which in combination with adaptability makes the RNA vaccine technology highly attractive against infectious diseases and for pandemic preparedness. Here, we review state of the art in the design and delivery of RNA vaccines for infectious diseases based on different RNA modalities, including linear mRNA, self-amplifying RNA, trans-amplifying RNA, and circular RNA. We provide an overview of the clinical pipeline of RNA vaccines for infectious diseases, and present analytical procedures, which are paramount for characterizing quality attributes and guaranteeing their quality, and we discuss future perspectives for using RNA vaccines to combat pathogens beyond SARS-CoV-2.</p>}}, author = {{Lokras, Abhijeet Girish and Bobak, Thomas Rønnemoes and Baghel, Saahil Sandeep and Sebastiani, Federica and Foged, Camilla}}, issn = {{0169-409X}}, keywords = {{Delivery systems; Infectious diseases; Lipid nanoparticles; Nanomedicine; RNA; Vaccines; Vaccinology}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Advanced Drug Delivery Reviews}}, title = {{Advances in the design and delivery of RNA vaccines for infectious diseases}}, url = {{http://dx.doi.org/10.1016/j.addr.2024.115419}}, doi = {{10.1016/j.addr.2024.115419}}, volume = {{213}}, year = {{2024}}, }